Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Epilepsy ll: Types01:22

Epilepsy ll: Types

35
Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
35
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.7K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

1.7K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.7K
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

2.3K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.3K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.3K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zorevunersen in Children and Adolescents with Dravet Syndrome. Reply.

The New England journal of medicine·2026
Same author

Smartphone videos for infantile epileptic spasms triaging and assessment (VISTA study): Impact of education and standardized clinical history on diagnostic accuracy.

Epilepsia open·2026
Same author

Pediatric epilepsy surgery: Global survey of invasive explorations.

Epilepsia·2026
Same author

Cognitive and behavioral clinical outcome assessments in children with developmental and epileptic encephalopathies: Issues and instruments.

Epilepsia·2026
Same author

Pediatric epilepsy surgery: Global survey of referral and presurgical evaluation practices.

Epilepsia·2026
Same author

AAV9-mediated targeting of natural antisense transcript as a novel treatment for Dravet syndrome.

Molecular therapy. Nucleic acids·2026

Related Experiment Video

Updated: Apr 29, 2026

Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study
11:29

Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study

Published on: August 15, 2025

3.2K

COL4A1 mutations should not be a contraindication for epilepsy surgery.

Apostolos Papandreou1, Martin M Tisdall, W K Chong

  • 1Paediatric Neurology Department, Great Ormond Street Hospital, Great Ormond Street, London, WC1N 3JH, UK, apostolos.papandreou@gosh.nhs.uk.

Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery
|May 28, 2014
PubMed
Summary

This case report details the first successful epilepsy surgery in a child with a collagen type IV alpha 1 (COL4A1) mutation. The procedure avoided complications, highlighting that COL4A1 mutations do not preclude surgical intervention for epilepsy.

More Related Videos

Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE
06:04

Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE

Published on: August 16, 2024

1.8K
Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
09:32

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients

Published on: December 18, 2016

13.7K

Related Experiment Videos

Last Updated: Apr 29, 2026

Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study
11:29

Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study

Published on: August 15, 2025

3.2K
Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE
06:04

Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE

Published on: August 16, 2024

1.8K
Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
09:32

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients

Published on: December 18, 2016

13.7K

Area of Science:

  • Neuroscience
  • Genetics
  • Vascular Biology

Background:

  • Mutations in collagen type IV alpha 1 (COL4A1) gene compromise vascular basement membrane integrity.
  • This genetic defect predisposes individuals to various neurological and vascular disorders, including epilepsy, stroke, and developmental delay.
  • COL4A1 mutations are associated with an increased risk of intracranial hemorrhage, particularly in pediatric patients undergoing anesthesia.

Observation:

  • A 6-year-old female with a confirmed COL4A1 mutation presented with drug-resistant epilepsy, cerebral palsy, and developmental delay.
  • The patient was deemed a candidate for corpus callosotomy following comprehensive presurgical evaluation.
  • Previous general anesthesia had been uneventful, and preoperative coagulation studies were within normal limits.

Findings:

  • A complete corpus callosotomy was performed without any intracranial hemorrhage or other perioperative complications.
  • Perioperative management focused on maintaining normotension and strictly avoiding anticoagulation.
  • This represents the first documented instance of complication-free epilepsy surgery in a pediatric patient with a COL4A1 mutation.

Implications:

  • The findings suggest that COL4A1 mutations, despite the associated hemorrhage risk, should not automatically contraindicate epilepsy surgery.
  • Individualized patient assessment, careful risk-benefit analysis, and informed consent are crucial for managing these complex cases.
  • This case expands the understanding of surgical management possibilities for epilepsy in patients with COL4A1-related vascular conditions.